The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The pathogenesis and treatment of Evans syndrome
V. Koneti Rao, MD, FRCPA, National Institute of Allergy and Infectious Diseases, Bethesda, MD, talks on the pathogenesis and treatment of Evans syndrome (ES), defined as an autoimmune condition that presents with two or more cytopenias – commonly autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Dr Rao emphasizes the importance of conducting a genetic evaluation of patients diagnosed with Evans syndrome to allow for specific, targeted treatment. Dr Rao also explains that in the future, striving toward more genetically or epigenetically targeted treatments is key in the management of chronic disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
